Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 19/20 | 1.00 |
| ▸ | MAOA | P21397 | 2/20 | 1.00 |
| ▸ | MAOB | P27338 | 2/20 | 1.00 |
| ▸ | BCHE | P06276 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ladostigil SCHEMBL3893996 | 1.00 | ACHE (1.00) | ACHEMAOAMAOBBCHE | |
| Ladostigil SCHEMBL678895 | 1.00 | ACHE (1.00) | ACHEMAOAMAOBBCHE | |
| SCHEMBL13853627 | 0.94 | ACHE (1.00) | ACHEMAOAMAOBBCHE | |
| Ladostigil SCHEMBL2387320 | 0.93 | ACHE (0.87) | ACHEMAOAMAOBBCHE | |
| Ladostigil SCHEMBL30579760 | 0.93 | ACHE (0.87) | ACHEMAOAMAOBBCHE | |
| SCHEMBL12043626 | 0.92 | ACHE (0.84) | ACHEMAOAMAOBBCHE | |
| SCHEMBL13853626 | 0.92 | ACHE (0.84) | ACHEMAOAMAOBBCHE | |
| SCHEMBL3895981 | 0.90 | ACHE (0.98) | ACHEMAOAMAOBBCHE | |
| SCHEMBL3895985 | 0.90 | ACHE (0.98) | ACHEMAOAMAOBBCHE | |
| SCHEMBL13449663 | 0.90 | ACHE (0.98) | ACHEMAOAMAOBBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1956904-A2 | USE OF LOW-DOSE LADOSTIGIL FOR NEUROPROTECTION | Yissum Research Development Company, of The Hebrew University of Jerusalem (IL) | 2008-08-20 | — | — | EP | claimed |
| WO-2007070425-A2 | USE OF LOW-DOSE LADOSTIGIL FOR NEUROPROTECTION | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2007-06-21 | — | — | WO | claimed |
| US-8609719-B2 | Propargylated aminoindans, processes for preparation, and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2013-12-17 | — | — | US | disclosed |
| US-20100093848-A1 | PROPARGYLATED AMINOINDANS, PROCESSES FOR PREPARATION, AND USES THEREOF | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2010-04-15 | — | — | US | disclosed |
| US-7476757-B2 | Reduction of indanone in presence of hydrogenation catalyst to form indanol; reacting with propargylamine under nucleophilic replacement; drug for central nervous system disorder | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-01-13 | — | — | US | disclosed |
| US-20080200720-A1 | Reduction of indanone in presence of hydrogenation catalyst to form indanol; reacting with propargylamine under nucleophilic replacement; drug for central nervous system disorder | TEVA PHARMACEUTICAL INDUSTRIES LTD. (US) | 2008-08-21 | — | — | US | disclosed |
| EP-1956904-A2 | USE OF LOW-DOSE LADOSTIGIL FOR NEUROPROTECTION | Yissum Research Development Company, of The Hebrew University of Jerusalem (IL) | 2008-08-20 | — | — | EP | disclosed |
| US-7375249-B2 | propynylaminoindans including alkoxy or alkylcarbamates derivatives, prepared by reduction of indanones in the presence of hydrogenation catalysts to form indanols and reacting the indanols with propargylamine under nucleophilic substitution to form drugs for the treatment of nervous system disorders | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-05-20 | — | — | US | disclosed |
| EP-1851188-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF ENANTIOMERIC INDANYLAMINE DERIVATIVES | Teva Pharmaceutical Industries Limited (IL) | 2007-11-07 | — | — | EP | disclosed |
| EP-1848689-A1 | CRYSTALS OF LADOSTIGIL TARTRATE, METHODS OF PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-10-31 | — | — | EP | disclosed |
| WO-2007070425-A2 | USE OF LOW-DOSE LADOSTIGIL FOR NEUROPROTECTION | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2007-06-21 | — | — | WO | disclosed |
| US-RE39616-E1 | Aminoindan derivatives | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2007-05-08 | — | — | US | disclosed |
| US-RE39616-E1 | Aminoindan derivatives | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2007-05-08 | — | — | US | disclosed |
| WO-2006120577-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF ENANTIOMERIC INDANYLAMINE DERIVATIVES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-11-16 | — | — | WO | disclosed |
| US-20060199974-A1 | propynylaminoindans including alkoxy or alkylcarbamates derivatives, prepared by reduction of indanones in the presence of hydrogenation catalysts to form indanols and reacting the indanols with propargylamine under nucleophilic substitution to form drugs for the treatment of nervous system disorders | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-09-07 | — | — | US | disclosed |
| WO-2006091656-A1 | CRYSTALS OF LADOSTIGIL TARTRATE, METHODS OF PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES, LTD (IL) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200720-A1 | Reduction of indanone in presence of hydrogenation catalyst to form indanol; reacting with propargylamine under nucleophilic replacement; drug for central nervous system disorder | IDH3A, IDH3B, INMT | ACHE 23/4885MAOA 451/4885MAOB 352/4885 |
| US-20060199974-A1 | propynylaminoindans including alkoxy or alkylcarbamates derivatives, prepared by reduction of indanones in the presence of hydrogenation catalysts to form indanols and reacting the indanols with propargylamine under nucleophilic substitution to form drugs for the treatment of nervous system disorders | ICMT, INMT, PNMT | ACHE 23/4885MAOA 537/4885MAOB 407/4885 |
| US-20100093848-A1 | PROPARGYLATED AMINOINDANS, PROCESSES FOR PREPARATION, AND USES THEREOF | DNPEP, PEPD, ACHE | ACHE 3/4885MAOA 482/4885MAOB 1332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.